Background BRCA1-mutated breast carcinomas may have distinct biological features, suggesting the involvement of specific oncogenic pathways in tumour development. The identification of genomic aberrations characteristic for BRCA1-mutated breast carcinomas could prove valuable in clinical testing for BRCA1-involvement in patients and could lead to a better understanding of the underlying process of oncogenesis.
Introduction
Breast tumours of BRCA1 germline mutation carriers have been shown to be primarily of the basal-like subtype (75-90%) [1, 2] . These basal-like breast carcinomas (BLCs) represent about 10 to 20% of all breast carcinomas [2, 3] and are generally high grade, triple negative ((ER-), (PR-), and (HER2/ERBB2-) and express high molecular weight cytokeratins (CK5/6, 14 and 17) [3] [4] [5] [6] .
High levels of genomic instability are frequently observed in BRCA1 mutated carcinomas and BLCs in general, both sporadic and hereditary [1, 7, 8] . Although frequent, these genomic aberrations mostly represent low copy number gains and losses of large DNA segments rather than (focal) high level amplifications [8, 9] . This observation fits well with the described role of BRCA1 in DNA damage response and DNA repair through homologous recombination (HR) [10] . Hyper-methylation of the BRCA1 promoter region and reduced BRCA1 mRNA expression levels have been observed in sporadic BLCs and could act as an alternative mechanism of BRCA1 inactivation [11] [12] [13] . However, the involvement of a dysfunctional BRCA1 gene in sporadic BLCs has also been questioned due to lack of somatic mutations in the BRCA1 gene [14, 15] . The observed similarities between BRCA1-mutated and BLCs have led to the suggestion that targeting a dysfunctional BRCA1-pathway, exploiting in particular a defective HR, might be effective in all BLCs [16] . However, platinum based chemotherapy and treatments with PARP inhibitors have shown inconsistent results in BLCs [17, 18] . For this reason, the role of a dysfunctional BRCA1 gene or pathway as a general characteristic of BLCs remains uncertain.
To allow discrimination between BRCA1-mutated and unselected sporadic/hereditary breast tumours, micro-array based comparative genomic hybridization studies (aCGH) have been used to identify characteristic genomic aberrations in BRCA1-mutated breast tumours [19] [20] [21] [22] [23] . Recent studies comparing BLCs with and without BRCA1 mutations have reported few or even no differential regions of genomic aberrations [1, 9, 24] . The use of such BRCA1 specific classifiers would facilitate the identification of women and their family members with unknown germline mutation status or undetected germline mutations. They might also prove valuable in assessing the pathogenicity of variants of unknown clinical significance [20] . Furthermore, the identification of driver genes in regions characteristic for BRCA1-mutated tumours could lead to a better understanding of the underlying process of oncogenesis and may provide novel clues for targeted therapies.
The aim of this study was to identify characteristic copy number aberrations (CNAs) for BRCA1-mutated breast carcinomas and to explore the genomic landscape of familial BRCAX (non-BRCA1/2) breast carcinomas. For this reason single nucleotide polymorphism (SNP) array data and gene expression data for 120 hereditary breast tumours were analyzed.
As the majority of the BRCA1-mutated breast carcinomas are found to be of the basal-like subtype, our primary analysis was restricted to BLCs. Initially, comparison of 27 BRCA1-mutated versus 14 BRCAX BLCs did not lead to the identification of many CNAs characteristic for the BRCA1-mutated BLCs. However, an unanticipated inter-tumour heterogeneity regarding the copy number and LOH profiles of the BRCA1-mutated BLCs was observed. Gene expression analysis indicated high numbers of tumour infiltrating lymphocytes (TILs) to be responsible for this observation. Copy number and LOH profiling was found to be hampered in a significant proportion of (BRCA1-mutated) BLCs due to high amounts of TILs. Optimal sample selection of tumours with low amounts of TILs allowed for the identification of BRCA1-associated CNAs capable of discriminating between BRCA1-mutated and BRCAX BLCs. The impact of TILs on genomic profiling was further substantiated by FACS sorting of tumour cells from formalinfixed, paraffin-embedded BRCA1-mutated triple negative breast carcinomas selected for high amounts of TILs.
Materials and Methods

Ethics Statement
This study has been approved by the medical ethical committee at Erasmus MC, and was performed according the Code of Conduct of the Federation of Medical Scientific Societies in The Netherlands.
Sample collection
Fresh-frozen specimens of primary breast tumours from female familial breast cancer cases were selected from the tissue bank of the Erasmus Medical Center Rotterdam. All cases had been screened for germline mutations in BRCA1, BRCA2 and for the CHEK2*1100delC mutation. The complete breast cancer cohort consists of 154 primary tumours and includes 26 tumours with a CHEK2*1100delC mutation, 47 BRCA1-mutated tumours, 6 BRCA2-mutated tumours and 76 non-BRCA1/BRCA2/CHEK2*1100delC (BRCAX) tumours. These non-mutant breast cancer cases all originated from families with at least two breast cancer cases in first or second degree relatives of which at least one had been diagnosed before the age of 60. The entire cohort is described in detail by Nagel et al. [25] . In this study, 120 tumour samples for which both SNP array and gene expression data is available were used for further analyses.
For validation purposes a publicly available dataset of 359 primary breast tumours, including 18 BRCA1-mutated BLCs, for which aCGH and gene expression data is available, was analyzed [1] . To further evaluate the impact of tumour infiltrating lymphocytes on copy number profiling in BLCs, the discovery set of a second publicly available dataset was used [26] . The discovery set of this study contains high resolution SNP array and gene expression data of 998 primary sporadic breast tumours including 118 BLCs. A final dataset consisting of 186 samples including 40 BRCA1-mutated breast tumours for which aCGH data and hematoxylin and eosin stained (H&E) sections of paraffin embedded tissue were available was obtained from the Netherlands Cancer Institute [27] .
For FACS sorting, archival, formalin-fixed, paraffin-embedded, (FFPE) germline BRCA1-mutated triple negative breast tumours were obtained from the FFPE tissue bank of the Department of Pathology, VUMC, Amsterdam, The Netherlands. Samples were handled according to the medical ethical guidelines described in the Code for Proper Secondary Use of Human Tissue established by the Netherlands Federation of Medical Sciences.
Mutation Screening
BRCA1, BRCA2 and CHEK2*1100delC mutation screening has been described [25] . BRCA1 mutation analyses in tumour DNA was performed identically, except that deletion screening by MLPA was not performed.
Gene expression microarrays
Total RNA was isolated from frozen sections using RNAzol B (Campro Scientific, Veenendaal, The Netherlands) and RNA quality and quantity was evaluated on an Agilent Bioanalyzer. Antisense biotinylated RNA was prepared and hybridized to Affymetrix hgU133_Plus_2.0 GeneChips, according to the manufacturer's guidelines (Affymetrix, Santa Clara, CA, USA). Gene expression signals were calculated using Affymetrix GeneChip analysis software MAS 5.0. Global scaling normalization was performed to bring the average signal intensity of the chips to a target of 100 prior to data analysis. The data was analyzed in Partek Genomics Suite (v6.6, Partek Inc.).
Classification of Intrinsic Molecular Subtypes
The intrinsic gene list was used to appoint the samples to molecular subtypes as described [28] . In short, the intrinsic gene list [29] was mapped to the corresponding probe-sets on the hgU_133_plus_2.0 array using Unigene Cluster Id's. The most variable probe-sets were used to cluster 120 familial samples using average linkage hierarchical clustering with correlation as a distance metric.
Copy number analyses by SNP arrays
To detect copy number aberrations, genomic DNA was isolated and hybridized to Affymetrix 500k SNP arrays and chip processing was performed according to Affymetrix's recommended protocols. In total, 120 samples were processed, consisting of 35 BRCA1, 5 BRCA2, 17 CHEK2*1100delC mutated and 63 BRCAX tumour samples. The array intensity .CEL files were processed by Partek Genomics Suite using default settings for background correction and summarization, results were corrected for GC-content and fragment length. Unpaired copy number analysis was performed in Partek Genomics Suite, comparing signal Log2 ratios to a custom created reference baseline of 90 female HapMap CEPH samples with European ancestry (CEU). The genomic segmentation algorithm was used to detect breakpoint regions and estimate copy number levels with stringent parameters (P<0.0001, >20 markers, signal/noise: 0.45). With an expected normal range of 2± 0.25 copies. Differences between the tumour groups (mutation class) for frequency of copy number aberrations (gained, lost, or unchanged) were calculated by employing a 3 x 2 Fisher's exact test (FE). Resulting p-values were not directly corrected for multiple testing. SNP array, gene and cytogenetic band locations are based on the hg18 Genome build.
For unsupervised hierarchical clustering of copy number data the called copy number states (gain, loss or neutral) of the segmentation data were used as distance metric. Agglomerative clustering was performed on these data by Euclidean distance and Wards method.
Identical settings for copy number analysis were applied in the validation cohorts. However, for the Netherlands Cancer Institute data set, copy number segmentation was also performed with less stringent settings (signal/noise: 0.3, expected normal range of 2±0.20). Gene expression profiling was not performed on these samples. Further analyses were performed on samples for which hormone receptor status information was available. The gene expression and SNP microarray data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number 54219.
LOH calling by detection of allelic imbalance
A segmentation based approach of allelic imbalances was used to identify regions of loss of heterozygosity (LOH). The B-allele frequencies of 120 breast tumour samples were generated in Partek Genomics Suite. Mirrored BAF profiles (mBAF) were used as previously described [30] . The resulting mBAF profiles were segmented in Partek Genomics Suite and LOH calling of segmented regions was done by applying a fixed allelic imbalance threshold of 0.76 and p-value <0.01. The same parameters used in segmentation of the copy number data were applied, except that a window size of 100 SNPs instead of 20 SNPs was used as a minimum number of genomic markers.
Analysis of BRCA1 promoter methylation BRCA1 promoter hyper-methylation was determined by methylation-specific PCR (MSP) after bisulfite treatment of DNA. Bisulfite modification of DNA to convert unmethylated cytosine residues to uracil was carried out using the EZ DNA methylation kit (Zymo Research, Orange, CA) following the manufacturer's protocol. A genomic DNA control sample was used as a negative control, and the same sample treated in vitro with SssI bacterial methylase was used as a positive control. Primer sequences were adapted from Wei et al. [12] . The PCR reaction was composed of an initial denaturation at 95°C for 5 minutes, followed by 37 cycles consisting of 30s at 95°C, 30s at 61°C, 45s at 72°C and ending with a final 5 minutes extension at 72°C. The PCR products were analyzed by electrophoresis and UV transillumination.
Correlating immune signature and copy number data Correlation of immune-infiltrate signatures and copy number profiles of each individual sample was performed by assigning a standardized measure for overall immune-infiltrate mRNA expression and correlating this to a global measure of copy number variation. For the expression measure the 618 identified probe-sets (differentially expressed between BRCA1-mutated BLCs grouped according to LOH profiles, see results section) were mean standardized and scaled to a standard deviation of 1. The sum of expression levels of these probe-sets for each individual sample was taken as measure of immune-infiltrate. For each sample, the genome-wide deviation from the diploid copy number state was calculated for all detected segments and the sum of these results was used as measure for global copy number aberrations.
Scoring of TILs in tumour sections
H&E stained frozen and FFPE sections were scored for the amount of infiltrating lymphocytes in the tumour by an experienced pathologist. This was performed by estimating the number of lymphocytes, and reported as a percentage of all nuclei present within that area.
Scoring BRCA1-associated genomic aberrations
To discriminate between BRCA1-mutated and BRCAX BLCs, a class prediction algorithm using a nearest shrunken centroids method with equal priors, imbedded in Partek Genomics Suite software, was applied. As input, mean copy number values from the segmentation results were used. Genomic regions used by this algorithm were found to overlap with the most significant regions as reported in the Fisher's exact test results. These regions in combination with the most frequently observed genomic aberrations present in all BLCs were used to define 12 regions of BRCA1-BLC associated copy number aberrations. These specific regions of copy number loss or gain were analyzed in cross platform validation data sets. Samples were scored for the amount of copy number aberrations (gains/losses) in these regions, when 9 or more regions harbor similar CNAs as determined for the BRCA1-mutated BLCs, samples are called as BRCA1-like. This threshold of 9 or more was chosen based on the primary data set whereby all cases with low immune-infiltrate levels of BRCA1-mutated origin were scored as BRCA1-like. For the Netherlands Cancer Institute validation set, samples were coded and results were disclosed after CNA scoring.
Tumour dissociation and DNA flow cytometry H&E-stained paraffin sections taken from 10 selected samples were scored by an experienced pathologist to determine the extent of TILs. Five samples with the highest amount of TILs (>40%) were selected for further analysis. Cell suspensions were prepared as described [31, 32] from four 50-μm sections per sample in duplo. Staining of the cells was performed as previously described [31] , with minor modifications (for details see Additional file 4).
For flow-sorting, vimentin-negative, keratin-positive tumour cell and vimentin-positive, keratin-negative stromal/immune cell fractions were separated using a FACSAriaIIu flow-sorter at 20 psi (BD Biosciences) with a 100-μm nozzle at a frequency of 32 kHz. The 488 laser line and the red 635 laser line were used for excitation. A 16p16y sort mask was applied. The following detector and filter settings were used during sorting: FITC fluorescence, detector E, 530/30 nm BP filter; APC fluorescence, detector C, 667/30 nm BP filter; PI fluorescence, detector C, 610/20 nm BP filter. A detector C-Area versus detector C-Width dot plot was used to gate out doublet and aggregates during sorting. After sorting, DNA was isolated using the Promega, Wizard Genomic DNA Purification kit.
Copy number profiling by shallow whole genome sequencing DNA derived from three cellular fractions extracted from three germline BRCA1-mutated breast carcinomas was sequenced at low coverage depth (~0.1-0.3 fold, for detailed sequencing statistics see Additional file 5). In total, 100 to 200ng of DNA (depending on availability) was used for library preparation with the Illumina TruSeq DNA v2 kit, as described previously [33, 34] . Barcoded libraries were pooled and run on an Illumina HiSeq 2500 (San Diego, CA, USA) for single end 50 cycle (SR50) sequencing. Sequencing reads were aligned to the human reference genome (build GRCh37 / hg19) with BWA [64] and PCR duplicates as well as ambiguous reads were filtered out. Next, the genome was divided into non-overlapping bins of 15 kbp, and the number of reads in each bin was counted. These counts were (1.) corrected (using GC content and mappability) and (2.) filtered using a blacklist derived from ENCODE [36] and 1KG [37] data (3.) log2-transformed (4.) median normalized, (5.) segmented and called with Partek Genomics Suite similarly as described for the SNP array CNA analysis. The hg18 based genomic coordinates of the BRCA1-associated CNAs were mapped to the hg19 genome build using the hg-Liftover tool from UCSC (http://genome.ucsc.edu/).
Results
BRCA1 status and Intrinsic sub-typing
Gene expression and SNP array analyses were performed on 120 familial breast carcinomas. The cohort consists of 35 BRCA1 mutated, 5 BRCA2 mutated, 17 CHEK2*1100delC mutated and 63 BRCAX carcinomas. In accordance with literature [24] , 77% of the BRCA1-mutated carcinomas (n=27) in this study are of the basal-like subtype, as are 14 BRCAX carcinomas. The remainder of BRCA1-mutated breast carcinomas is predominantly of the luminal-B subtype, see Additional file 1 for complete sample information. Evidence for BRCA1 promoter hyper-methylation was detected for 6 samples by MSP, amongst which three BRCAX tumours of the basal-like subtype.
Integrated Genomics analyses
To gain insight into the genomic characteristics of BRCA1-mutated breast carcinomas, copy number and LOH profiling based on high-resolution SNP arrays was performed. Copy number profiles for most of the BRCA1-mutated tumours, and basal-like carcinomas (BLCs) in general, showed many CNAs. Tumours of the luminal subtypes displayed more heterogeneity in the amount of aberrations, and had less aberrations overall compared to the BLCs. The most common aberrations in all tumour samples include regions of copy number gain of chromosomal arms 1q, 8q and 16p and copy number losses of chromosomal arms 8p and 16q in accordance with previous observations [1, 7, 8, 24] . Unsupervised hierarchical clustering of genomewide copy number profiles showed clustering of the majority of BLCs, irrespective of mutational status ( Figure 1A ). Supervised comparison of the copy number profiles of the BRCA1-mutated BLCs versus BRCAX BLCs resulted in very few regions of copy number difference. Although few, these regions are in accordance with previous reports [33] . Regions include CNAs on chromosome 3 and copy number loss on chromosomal arm 15q (data not shown).
In agreement with the copy number analysis results, loss of heterozygosity (LOH) analysis showed marked differences in the number of regions with LOH between the basal-like and other subtypes ( Figure 1B) . LOH was more frequently observed in the BLCs. Copy neutral LOH on the long arm of chromosome 17, encompassing the BRCA1 locus, was found to be the most recurrent region of LOH in both BRCA1-mutated (9/27) and BRCAX BLCs (6/14) ( Figure 1B as indicated by the black arrow).
Clustering of the copy number profiles suggests that the BLCs can roughly be subdivided into 2 groups ( Figure 1A ). One group ( Figure 1A , group 1) is characterized by many CNAs (high CIN (here used as definition for high numbers of CNAs)) and tight co-segregation by unsupervised hierarchical cluster analysis, and a second group ( Figure 1A , group 2) with markedly fewer CNAs (low CIN) that cluster more loosely within the bulk of the luminal samples. Various regions of LOH were identified in the high CIN group, and only very few in the low CIN group.
By integrating copy number and LOH, the subdivision of BRCA1-mutated basal-like samples could be further refined into three groups ( Figure  1B ); 1-I) a group which is characterized by high CIN and LOH at the BRCA1 locus, 1-II) a group with high CIN but without LOH at the BRCA1 locus, and 2) a low CIN group. The copy number frequency plots of these 3 groups are shown in Figure 1C . The chromosomal regions of CNAs are mostly identical between the groups. However, the frequency with which they are found is remarkably different. The frequencies of identical CNAs are highest in the BRCA1 samples characterised by high CIN and LOH at the BRCA1 locus (group 1-I) and lowest in the low CIN group (group 2). Group 1-II shows CNAs at intermediate frequencies, with some genomic regions reaching identical frequencies as group 1-I. figure 1A . Bottom row column indicates LOH at the BRCA1 locus (BRCA1 LOH: black). Green indicates copy neutral LOH, red; copy number gain with LOH and blue; copy number loss and LOH. C, the frequency (vertical axis) of gains (red) and losses (blue) is displayed for the 3 BRCA1 groups.
BRCA1 mutation analyses in tumour material
The conservation of a functional copy of the BRCA1 gene could be causative for the difference in CNA profiles between the high and low CIN groups. Therefore, we questioned whether the observed heterogeneity of the BRCA1-mutated BLCs could be explained by haplo-insufficiency of the BRCA1 gene. If tumours in the low CIN group have retained a functional copy of the BRCA1 gene this could explain their relative stable CNA profile. In contrast, the tumours in the high-CIN LOH group are expected to have lost their wild-type BRCA1 allele. To explore this possibility, BRCA1 mutation scanning was performed on tumour material in 6 BRCA1-mutated BLCs in the high CIN LOH group, and 4 BRCA1-mutated BLCs in the low CIN group. In all samples the reported germline mutations could be confirmed but no additional mutations were identified. Complete loss of the BRCA1 wild-type allele is therefore evident in the BRCA1-mutated BLCs with high CIN and LOH at the BRCA1-locus. Whereas the low CIN BRCA1-mutated BLCs could have retained a copy of the wild-type BRCA1 allele. To further explore this unexpected observation, supervised mRNA analysis was performed.
Identification of an immune response mRNA signature
Gene expression analysis by means of ANOVA, with LOH at the BRCA1 locus as single factor, resulted in 618 differentially expressed probe-sets passing a step-up FDR p-value of 0.05. These 618 probe-sets could be mapped to 458 uniquely annotated genes (Affymetrix annotation NA33). Gene ontology analysis using the DAVID bio-informatics tool [38, 39] with Affymetrix probe-set identifiers as input, identified the term immune response (FDR corrected p-value< 1E-5) to be the most enriched biological process.
Correlation of Immune signature and CNAs
Based on the results of the pathway analysis, we hypothesized the immune signature to be mainly due to tumour infiltrating lymphocytes (TILs). Immune responses in breast carcinoma is a widely described phenomenon, especially with respect to patient survival (for review see Mohammed et al. [40] ). To investigate the impact of the immune signature on CNA detection, the correlation between the relative amount of the immune signature and genome-wide measured CNAs was analyzed. Figure 2 shows that with decreasing values of the immune signature, amounts of measured CNAs increase (r s =-0.66, p-value< 0.001). Furthermore, the mean copy number measurements of the most frequently altered genomic regions in BLCs (i.e. loss of chromosome 5q11) are seen to be closer to the diploid state with increasing levels of the immune signature (data not shown). Samples in which LOH could be detected primarily represent the samples with the lowest values of the immune signature. Identical observations were made for the BRCAX BLCs. A small fraction of tumours from other intrinsic subtypes are also observed to have high immune signature mRNA levels. 
Confirmation of the mRNA immune signature
To confirm the presence of varying amounts of TILs amongst the BLCs, the proportion of lymphocytic nuclei within the tumour samples was assessed on H&E-stained frozen sections. In total 96 samples could be analyzed, including 19 BRCA1-mutated and 11 BRCAX BLCs. For the BLCs, the observed percentages of TILs ranged from 5 to 85%, with a mean percentage of 42%. Figure 3A shows the significant correlation of these percentages with the mRNA based immune signature (r s =0.74, p-value< 0.001). The distributions of TILs throughout the sections were found to be very heterogeneous. Predominant presence of TILs (small, compact, darkly stained cells) was seen at the outer borders of the more solid tumour fields ( Figure 3B ), 'flowing' inwards to more central regions of the carcinoma ( Figure 3C ). 
Optimal Sample Selection
To select for samples with low number of TILs, hierarchical clustering of expression data of all BLCs based on the immune signature probe-sets was used ( Figure 4A ). Following this approach, 8 BRCA1 and 5 BRCAX BLCs with lowest level of this expression signature were selected for further analysis. Copy number analyses on this selection of samples resulted in frequency plots for both the BRCA1-mutated and BRCAX BLCs reaching levels of 80-100% in many genomic regions, something which was not seen before except for regions on chromosome 1 and 8. These latter regions have the highest mean copy numbers. Importantly, more copy number regions of significant difference between the BRCA1-mutated and BRCAX tumours could now be detected. Figure 4B and C display the frequency plots and Fisher's exact test results of the selected BRCA1-mutated and BRCAX BLCs. Regions of significant copy number difference (not corrected for multiple testing) include copy number losses on chromosomal arms 7q, 11p, 14q, and 15q and gains of chromosomal arms 8q, 9q, and 15q. Some of these regions, such as the copy number losses of chromosmal arms 11p and 14q, seem to be associated with BRCAX status. Samples from the red branch with relatively low level of immune signature are selected for further copy number analysis. Indicated in red and blue are BRCA1-mutated BLCs with and without detectable LOH at the BRCA1 locus respectively, green indicates the BRCAX BLCs. B, the frequency (x-axis) of gains (red) and losses (blue) are displayed along chromosomes 1 to X (y-axis) for 8 BRCA1-mutated (top panel) and 5 BRCAX (bottom panel) BLCs selected for a low immune signature. C, Fisher's exact test is used to determine regions of differential copy number aberrations between the BRCA1-mutated and BRCAX BLCs. The dotted line represents a p-value threshold of 0.05 (not corrected for multiple testing). The regions above the threshold are considered to be significantly different between the groups. P-values are -log 10 transformed BRCA1-mutated BLC associated genomic aberrations. Genomic analyses following sample selection based on low mRNA values for TILs, allowed the identification of BRCA1-mutated BLC associated CNAs. A class prediction algorithm using a nearest shrunken centroid method, identified 8 genomic regions (5 regions with copy number losses and 3 regions with copy number gains) associated with BRCA1-status. These genomic regions include copy number gain of the proximal tip of chromosomal arm 3p, copy number loss of a more distal region on chromosomal arm 3p and copy number loss of chromosomal arm 15q. These regions were previously identified in other studies [19, 20, 22, 23] and already observed in this study prior to sample selection. Other regions however, such as copy number losses at chromosomal arms 7q, 13q, and 17p and copy number gains on chromosomal arms 9q and 15q, were not previously identified. See Figure 5B for details.
These CNAs proved capable of discriminating between the BRCA1-mutated and BRCAX BLCs after sample selection for low amounts of TILs. However, cross-platform applicability of such algorithms is problematic, and since the used sample size was limited after sample selection, validation in other cohorts was a necessity. For this reason we developed a simple method applicable to copy number data for all aCGH/SNP platforms, and copy number data in general.
The eight regions mentioned above together with the 4 most frequently altered genomic regions found amongst all BLCs (2 regions with copy number losses (chromosomes 4 and 5) and 2 with copy number gains (chromosomes 8 and 10)), were used to discriminate between BRCA1-mutated BLCs and other tumours of the basal-like and other intrinsic subtypes (Tables 1 and 2 , regions of BRCA1-associated CNAs). Using these regions, samples were scored for the number of these specific CNAs and samples with a chosen threshold of 9 or more CNAs are labeled as BRCA1-like. Table 1 . BRCA1 associated copy number gains. Chromosome  start  end  3  3866308  10719396  8  101981161  129288230  9  94909458  115239031  10  101955  28140907  15 90224005 97940195
Copy Number Gain
Hg18 based genomic regions of BRCA1-associated CNAs (gains). Table 2 . BRCA1 associated copy number losses. Chromosome  start  end  3  51130455  64449381  4  24424555  41258860  5  75800618  86398661  7  102291383  122355559  13  33885792  49037828  15  28016572  41141219  17  6001240  12559716 Hg18 based genomic regions of BRCA1-associated CNAs (losses).
Copy Number Loss
In our data set, the BRCA1-mutated BLCs selected for low TILs, were found to have 9 to 12 of these specific CNAs, while the BRCAX BLCs had 8 or less. Figure 5 shows the number of BRCA1-related CNAs found in all 120 familial breast carcinomas, plotted against the measured immune signature values. Clearly, BRCA1-mutated BLCs with few TILs harbor the most BRCA1-related CNAs. In a number of BRCA1-mutated BLCs with medium amounts of TILs many of these CNAs are still detected. However, in the BRCA1-mutated BLCs with the highest amount of immune signature levels no or only very few of these CNAs are detected. BRCAX BLCs and samples of other subtypes have fewer of these specific CNAs. Tumours of the luminal subtypes generally have low immune signature mRNA levels. However, a notable proportion of tumours of mainly the Her2Neu and luminal B subtypes were also found to have high immune signature values. High immune signature mRNA levels are also found in the 3 BRCAX BLCs with BRCA1 promoter hypermethylation, making it difficult to assess a possible genomic resemblance with BRCA1-mutated BLCs in this sample set. Figure 5 . Scoring of BRCA1-associated CNAs in relation to immune signature levels. BRCA1-mutated BLCs (red circles) with low immune signature levels (vertical axis) have a score of 9 to 12 BRCA1 associated CNAs (horizontal axis). BRCAX BLCs (green circles) with similar immune signature levels have less of these specific CNAs. This is also seen for samples of other subtypes ((including BRCA1-mutated) grey circles).
Validation of BRCA1-associated CNAs and impact of TILs
To validate our findings, a publicly available dataset of 359 primary breast tumours, including 18 BRCA1-mutated BLCs, for which aCGH and gene expression data are available, were analyzed [1] . The presence of TILs in BLCs was assessed in two ways. Firstly, the mRNA data were filtered on gene symbols common with the 458 unique genes from our mRNA immune signature. Hierarchical clustering analysis clearly showed groups with differential gene expression correlated with CNA levels. A second, more unbiased method was performed by comparing expression data of the familial BLCs analogous to our own approach. Because LOH data is not available for aCGH data, the familial BLCs were subdivided into two groups of similar size according to the level of CIN. Supervised mRNA analysis on these groups identified 542 clone id's to be differentially expressed between these groups. The Gene Ontology term immune response was found to be highly significant associated with these clone ids with a p-value< 1E-5. Figure 6A shows the significant correlation of this set of clone id's with the measured levels of CNAs in primary familial BLCs with and without BRCA1 mutations (r s = -0.58, p-value< 0.001). Figure 6 . Correlation of TILs with CNAs and scoring of BRCA1-specific CNAs in independent data sets. A, correlation of mRNA and genome-wide CNAs in familial primary BLCs with (red circles) and without (green circles) BRCA1 mutation, from the Jonsson et al. data set [1] . B, correlation of mRNA and genome-wide CNAs in sporadic BLCs from the discovery data set of Curtis et al. [26] , circles in light-blue represent CNA devoid tumours, other colours represent different subgroups of BLCs. C, frequency plots of the BRCA1-mutated BLCs (n=14) called as BRCA1-like (top panel) and not-called as BRCA1-like (bottom panel) in the Netherlands Cancer Institute data set [27] .
Of all 359 primary breast tumours that were assessed for the amount of BRCA1-associated CNAs, 10 samples were found to have 9 or more of these CNAs. Of these samples 6 are BRCA1-mutated BLCs, 1 sample is a BRCA1-methylated BRCAX BLC, 1 sample is a BRCA1-methylated sporadic BLC, 1 sample is a BRCA2-mutated BLC and the remaining sample is a BRCAX BLC of which no further information is available. The frequency plot of gains and losses for the 6 BRCA1-mutated BLCs (data not shown) shows identical regions and frequencies of CNAs as compared to our samples after sample selection ( Figure 4B ).
To further evaluate the impact of tumour infiltrating lymphocytes on copy number profiling in BLCs, the discovery set of a second publically available dataset was used [26] . The discovery set contains high resolution SNP array and gene expression data of 998 primary sporadic breast tumours including 118 BLCs. The mRNA data were again filtered for overlapping genes with our mRNA immune signature, for each overlapping gene the probe-set with the highest standard deviation was used in the analysis, resulting in 401 probe-sets which were correlated to genome-wide levels of CNAs ( Figure 6B ). Again a significant correlation between immune signature and CNA levels was seen (r s =-0.52, p-value< 0.001). However, a sizeable fraction of samples with low to intermediate levels of CNAs was found to have greatly varying immune signature levels. Samples with the highest immune signature levels were found to be amongst those samples with the least reported CNAs. Part of these samples were previously reported to belong to a specific subgroup of CNA devoid tumours exhibiting a strong immune and inflammation signature ( Figure 6B , light-blue circles [26] ).
A final dataset consisting of 186 micro-dissected samples including 39 BRCA1-mutated triple negative and 49 sporadic triple negative breast tumours for which aCGH data are available, was obtained from the Netherlands Cancer Institute [27] . For 19 BRCA1-mutated samples sections of paraffin-embedded tissue were available. After copy number analysis of all 186 samples, 9 samples were found to have 9 or more BRCA1-associated CNAs. Six of these samples are BRCA1-mutated and 2 samples BRCA1-methylated. All are triple negative breast carcinomas.
Because the number of BRCA1-mutated samples scored as such was lower than expected, copy number analysis was also performed with less stringent parameters. With these settings 22 samples were found to have 9 or more BRCA1-associated CNAs. Of these samples 14 are BRCA1-mutated and 3 BRCA1-methylated. For the called BRCA1 mutated samples, the reported frequencies and genomic coordinates of CNAs are highly similar to those reported for our samples and the samples reported as BRCA1-mutated in the Jonsson et al data set [1] . However, some differences were also observed. The copy number frequency plots for the called and not called BRCA1 mutated samples are shown in Figures 6C and  6D respectively. The frequency by which genome wide CNAs are detected is again much higher in the BRCA1-called samples compared to the not called samples. This is most apparent for copy number losses on for example chromosomal arms 3p, 4p, 5q, 15p and 17p.
For 19 BRCA1-mutated samples H&E stained sections of paraffinembedded tissue were available and scored for TILs. These samples were scored within the area outlined for micro-dissection. BRCA1-mutated samples with 9 or more BRCA1 associated CNAs were found to have a lower mean percentage of TILs of 27%, as compared to 41% TILs seen in the remaining BRCA1-mutated samples (not-called as BRCA1). However, these results are not significantly different (Mann-Whitney; p=0.101).
DNA flow cytometry and shallow whole genome sequencing
To evaluate the impact of TILs on whole genome copy number profiling, five triple negative germline BRCA1-mutated breast carcinomas with a TIL percentage of 40% or higher were selected for DNA flow cytometry. For all samples two cell suspensions from paraffin embedded tissue sections were prepared. Of these cell suspensions one was used to obtain an unsorted total DNA fraction (comparable to what is analyzed in the primary set of tumours), while the other suspension was sorted into a vimentin-negative, keratin-positive tumour cell fraction and a vimentin-positive, keratin-negative stromal/immune cell fraction. Sufficient DNA for all three fractions was obtained for three samples to be further analyzed by whole genome shallow sequencing. The resulting Log2 ratios for 166k data points were analyzed identically to the SNP array data analysis. Copy number profiles are plotted using ggplot2 software [41] . Figure 7 shows microscopy images of HEstained paraffin-embedded sections (A, B), a vimentin versus keratin dot plot (C) and copy number profiles (D) for all three cellular fractions of one BRCA1-mutated triple negative breast carcinoma. Additional file 2 shows microscopy images, vimentin versus keratin plots and copy number profiles for the other two FACS sorted samples.
The copy number profiles of the unsorted fractions show a few chromosomal regions with copy number gains. These copy number profiles resemble the SNP array copy number profiles for the BLCs with the highest amounts of TILs. The stromal/immune fractions typically show a diploid copy number profile as expected. Copy number profiles from the tumour fractions display many gains and losses of large chromosomal regions. As expected, the copy number gains seen in the unsorted fractions match those regions with the highest mean copy numbers in the sorted tumour fraction profiles (chromosome 1q, 8q, 9p). The copy number profiles of the sorted tumour fractions were highly similar to those seen by SNP array analysis for the BRCA1-mutated BLCs with the lowest amounts of TILs. However, instead of copy number neutral LOH at the BRCA1 locus, copy number losses of the entire long arm of chromosome 17 are found in the flow sorted tumour fractions. For these samples the reported pathogenic BRCA1 germline mutations were all confirmed by Sanger sequencing in all fractions. In the unsorted and normal/immune fractions the mutations are seen in a heterozygous state, while the mutant allele is seen predominantly in the sorted tumour fractions (data not shown).
Nine BRCA1-associated CNAs were present in two of the samples. The remaining sample was found to have 6 BRCA1-associated CNAs. This sample has a copy number gain on chromosome 13q and no copy number change on chromosome 15q, where copy number losses were expected. After merging the copy number profiles of the three unsorted and sorted tumour cell fractions with the SNP array copy number profiles, this sample (tumour fraction) with lowest BRCA1-associated CNAs appeared to cluster together with high CIN luminal B carcinomas, within a predominantly BLC branch, in unsupervised hierarchical clustering of copy number data. Whereas the tumour fractions of the other two tumours cluster together with the bulk of the BLCs, see Additional file 3. 
Discussion
The aim of this study was to identify specific genomic characteristics of germline BRCA1-mutated breast carcinomas. For this purpose, genome wide copy number, LOH, gene expression and BRCA1 promoter hypermethylation data were analyzed for a familial cohort of 120 breast carcinomas. Since BRCA1-mutated breast carcinomas are primarily of the basal-like subtype we restricted our main analyses to this intrinsic subtype.
Integration of copy number and LOH profiles showed a marked heterogeneity amongst the BRCA1-mutated BLCs which was found to be associated with high amounts of tumour infiltrating lymphocytes (TILs). Examination of frozen sections by a pathologist confirmed the presence of large numbers of TILs in especially BLCs. An inverse correlation was seen between the amount of TILs and genome-wide levels of CNAs measured in BLCs. Also, allelic imbalances are readily observed in samples with low amounts of TILs, as exemplified by the frequent detection of copy neutral LOH on chromosome 17. In contrast, samples with high levels of TILs often show aberrant or scrambled BAF-profiles even when CNAs are detectable. From these observations it was deduced that genomic material from infiltrating immune cells, mostly lymphocytes, interferes with the ability to measure tumour specific DNA-content, impairing copy number and LOH profiling. Varying amounts of TILs are most likely causative for the observed inter tumour heterogeneity amongst the (BRCA1-mutated) BLCs.
Approximately two thirds of the BRCA1-mutated BLCs are found to have TIL percentages of 35% or higher reaching 85% TILs. These TIL percentages were initially underestimated when tumor cell percentages were established for these samples. Similar observations are seen in the BRCAX BLCs. Discrepancies between TIL percentages as scored by the pathologist and as measured by mRNA analysis can likely be explained by the large heterogeneity regarding the distribution of TILs throughout the tumour tissue.
A well known difficulty in DNA-copy-number determination by aCGH and SNP array analyses is variable tumor purity due to normal DNA contamination. Other such problems arise from intra-tumor heterogeneity, aneuplody/polypoidy and technical artifacts. For these reasons various methodologies have been proposed to deal with such issues [42] . However, such methods have not been applied in most work on genomic profiling of breast carcinomas. Furthermore, the extreme percentages of TIL contamination identified in our analyses restrain such methods to be applied. This is best seen by comparing the genomic profiles generated after FACS sorting and subsequent shallow whole genome sequencing analyses. The genomic profiles in the unsorted tumor fractions display, besides a few apparently low-level copy number gains, flat-line copy number profiles. Whereas the sorted tumor fractions show many copy number gains and losses (Figure 7 C) . We noticed that the effect of TILs on genomic profiling of tumors is underestimated leading to misinterpretation of data, at least in breast cancer research. Micro-dissection of tumor material can be used to exclude TILs located at the outer borders of the tumor cell mass. However, TILs located in between tumor cells cannot be removed in this way.
The correlation between a TIL representing mRNA signature and genome wide measurements of CNAs was validated in two previously published data sets. The data set published by Jonsson et al. [1] was used to validate the correlation between TILs and CNA measurements in a familial breast cancer setting resembling our own cohort, while the data set of Curtis et al. [26] demonstrates a significant correlation between TILs and CNAs in sporadic BLCs. From our analyses it seems that the correlation between TILs and CNAs is not as prominent in sporadic BLCs as compared to familial BLCs, as low CIN sporadic BLCs with low mRNA values were readily seen. Interestingly, sporadic BLCs with the highest immune signature values in this last data set were indeed identified as CNA devoid by the authors. Subsequent gene expression analysis by the authors identified an immune response and inflammation signature to be characteristic for the genomic subgroup where these samples were assigned to. This study shows that the absence of CNAs in these samples is likely due to measuring mostly genomic DNA of TILs instead of tumour DNA.
Sporadic BLCs with few CNAs are also reported in a study by Chin et al. [43] . Here a novel genomic stable subtype of ER negative breast cancer is reported, characterized by a 37 gene expression classifier with marginal statistical associations with immune and inflammatory responses. Reports of BRCA1-mutated breast carcinomas with few CNAs are scarce. However, genomic stable BRCA1-mutated BLCs are reported by Stefansson et al. [9] . These authors report a simple genomic profile subgroup resembling a BRCA1-related subgroup but displaying considerably less complex genomes. These tumours displayed gains at chromosomes 1q and 8q, typically reported as regions with the highest mean copy number gains in BLCs. Again, results from this study suggest that the observations are likely explained by the presence of TILs in this subgroup of tumours.
After sample selection for low levels of TILs, 8 BRCA1-mutated and 5 BRCAX BLCs remained for further analysis. In spite of this small sample size, differential regions of CNAs could be identified between these tumour groups. Some of these regions were reported before; while others were previously not considered as significantly associated with BRCA1-mutation status. Furthermore, following sample selection, the frequencies of recurring CNAs are much higher compared to our initial results and literature reported observations without this sample selection. Exemplary for this is the BRCA1-mutated tumour specific loss of chromosome 15q11-21, which has been implicated in the loss of TP53BP1 in BRCA1 related oncogenesis [44] . In literature, this region was found to be lost in approximately 35% of BRCA1-mutated tumours. Our initial observations yielded similar results. However, after sample selection, this frequency increased to 100% in the BRCA1-mutated BLCs.
Specific CNAs at 8 genomic regions proved to be capable of discriminating between the selected BRCA1-mutated and BRCAX BLCs. Together with the 4 most recurring CNAs found in all BLCs, these regions proved capable of discriminating between BRCA1-mutated BLCs and breast carcinomas of other subtypes in our data set as well. These results were validated in 2 independent cohorts, typically identifying one third of the BRCA1-mutated BLCs as such. This is in line with our findings that approximately two thirds of the BRCA1-mutated BLCs exhibit extensive lymphocytic infiltration, hampering copy number profiling and subsequent scoring. CNA scoring of the Netherlands Cancer Institute data set with less stringent parameters scored 17 samples correctly (either BRCA1 mutated or methylated) but also 5 samples incorrectly as BRCA1-like. A possible explanation could be a defective BRCA1 gene caused by other means or incorrect calling of CNAs in noisy samples due to less stringent parameter settings. Interestingly, in both validation-sets, a number of sporadic basallike/triple negative breast carcinomas reported to have BRCA1 promoter hyper-methylation are also scored as BRCA1-like. This suggests that at least a proportion of BRCA1 promoter hyper-methylated breast carcinomas follow an oncogenic pathway leading to similar CNAs as observed in BRCA1-mutated BLCs.
The CNA frequency plots of the BRCA1-mutated basal-like/triple negative breast carcinomas scored with 9 or more BRCA1-associated CNAs are very similar between the three data sets. This holds true not just for these 9 genomic regions, but for other regions as well. However, some interesting differences are also seen. For example, the observed BRCA1-specific copy number gain of chromosome 15q in our data set is not seen in comparable frequencies in the other two data sets. Also, a BRCA1-specific copy number gain of chromosome 3q is more frequently seen in the Jonsson et al. [1] and Netherlands Cancer Institute data sets [27] . These observations suggest genomic heterogeneity even amongst the BRCA1-mutated breast carcinomas. Small sample sizes and differences in copy number array platforms could play a role in these observations. This study implies that BRCA1 driven oncogenesis essentially leads to similar CNAs in most BRCA1-mutated BLCs. However, the ability to measure these BRCA1-related CNAs depends on the tumour cell percentage of the sample, especially in relation to the quantity of TILs within these carcinomas. As a result, two thirds of the BRCA1-mutated BLCs are not being recognized to have similar CNAs. Alternatively, a biased selection has occurred for a subgroup of BRCA1-mutated BLCs characterized by specific CNAs favoring the escape of immune system responses.
To address these possibilities we performed multi-parameter DNA flow cytometry analysis of three germline BRCA1-mutated triple negative breast carcinomas which were selected for high amounts of TILs. The copy number profiles obtained by shallow whole genome sequencing (WGS) of the sorted tumour fractions were highly similar to those of BRCA1-mutated BLCs with low amounts of TILs, except for the striking observation that the tumour fractions of the high TIL cases showed a loss of the complete long arm of chromosome 17, instead of copy neutral LOH as observed in the low TIL cases. This difference in acquiring complete BRCA1 deficiency, i.e. copy neutral LOH or deletion, may thus be somehow linked to the immune response.
Conclusions
Overall, we have demonstrated the presence of large quantities of TILs in especially BLCs and their impact on copy number (and LOH) profiling by SNP-array, aCGH and shallow WGS analyses. Research on (BRCA1-mutated) BLCs can particularly benefit from these findings. Future studies aimed at further defining BRCA1-associated genomic aberrations should include a selection step specifically aimed at selecting for low quantities of TILs, or otherwise diminish the effect on genomic profiling of these cells for example by multi-parameter DNA flow cytometry as shown in this study and other studies performed on cervical and colorectal carcinomas [45, 46] . Also, this approach will most likely prove valuable in next generation sequencing studies on tumour material.
Based upon differential CNAs between a small number of BRCA1-mutated and BRCAX BLCs with low amounts of TILs it proved possible to construct a simple scoring method to identify BRCA1-mutated basallike/triple negative breast carcinomas with high specificity. A similar analysis with a larger sample set could fine-tune these results and perhaps give insight into the differences between BRCA1-mutated BLCs with differential mechanisms for losing the wild-type BRCA1-allele.
The clinical use of classifiers to identify potential BRCA1-mutated patients or evaluate BRCA1 variants of unknown significance from tumour material most likely suffers from the consequences of high quantities of TILs in a sizeable fraction of patients. Care must be taken so that BRCA1-mutated breast carcinomas with high quantities of TILs are not misinterpreted.
Future research is aimed at identifying genes within the BRCA1-associated CNAs contributing to BRCA1 driven oncogenesis, which could ultimately lead to a better understanding of the etiology of BRCA1 tumours and possibly novel therapeutic options.
